Prognostic role of N-terminal prohormone of brain natriuretic peptide for patients in the medical intensive care unit with severe sepsis

KS Reshmi1, Manju Sara Oommen2, Preeti Belgundi3, Tisa Paul1, Asmita Anilkumar Mehta1

1Department of Respiratory Medicine, Amrita Institute of Medical Sciences, Kochi, Kerala India, 2Consultant Pulmonologist, Allain Hospital UAE, 3Asthma Allergy Centre, Davangere, Karnataka, India

ABSTRACT

Background: Sepsis is an important cause of mortality in intensive care units worldwide. The increased levels of N-terminal prohormone of brain natriuretic peptide (NT-pro BNP) are related with dysfunction of the cardiovascular system and systemic inflammation. It is uncertain whether this increase reflects sepsis-related cardiac dysfunction that translates to poorer outcomes. Aims and Objectives: The primary aim of this study was to evaluate the prognostic role of NT-pro BNP on the outcome and duration of hospital stay of patients admitted with sepsis. The secondary objective was to identify other associated risk factors for mortality in sepsis. Patients and Methods: The patients who presented to emergency room with diagnosis of suspected sepsis were studied. Risk factors associated with outcome were studied by univariate analysis. The variables having statistical significance were further included in multivariate analysis to identify the independent predictors of mortality. Results: A total of 215 patients with sepsis were included in this study. In univariate analyses, NT-pro BNP, procalcitonin, need of mechanical ventilation (MV), blood culture positivity, chronic kidney disease-chronic liver disease CKD-CLD, and diabetes mellitus were predictors of prolonged hospital stay, and it was same for multivariate analysis excluding procalcitonin. In univariate analysis, NT-pro BNP, MV, and DM were risk factors associated with mortality but in multivariate analysis showed significance only with MV and DM. Conclusion: There was a statistically significant correlation between NT-pro BNP levels and mortality. The other factors associated with increased mortality were diabetes mellitus and need of MV. In addition to the above factors, the presence of CKD and CLD was associated with increased duration of hospital stay. There was concordance between increased NT-pro BNP and elevated troponin T, s creatinine, need of MV, and CKD.

KEY WORDS: Mortality, N-terminal prohormone of brain natriuretic peptide, sepsis

Access this article online

Quick Response Code:  
Website:  www.lungindia.com  
DOI:  10.4103/lungindia.lungindia_138_20

How to cite this article: Reshmi KS, Oommen MS, Belgundi P, Paul T, Mehta AA. Prognostic role of N-terminal prohormone of brain natriuretic peptide for patients in the medical intensive care unit with severe sepsis. Lung India 2021;38:438-41.
INTRODUCTION

The 108-amino acid prohormone B-type natriuretic peptide (BNP) and its product 76-amino acid N-terminal prohormone of brain natriuretic peptide (NT-pro BNP) are secreted in response to atrial or ventricular wall stretch or myocardial ischemia by cardiomyocytes into the blood.[1‑2] BNP is cleared through internalization by cells that express BNP receptors, while renal clearance is the main mechanism for NT-pro BNP. This difference accounts for the difference in plasma concentration half-lives and is likely to be responsible, in part, for delayed clearance in patients with sepsis. That is why, the half-life of BNP is 20 min and that of NT-pro BNP is 1–2 h.[3]

BNP is considered a marker of left ventricular end-diastolic pressure[4] and has been proven to be a useful diagnostic tool to differentiate dyspnea caused by congestive heart failure (CHF) from noncardiac dyspnea in patients presenting at the emergency room.[5,6] It has been shown that a normal BNP level (<80–100 pg/ml) has a high negative predictive value to exclude CHF, whereas a markedly elevated BNP has a high positive-predictive value for CHF.[7]

Sepsis is defined as life-threatening organ dysfunction caused by dysregulated host response to infection.[8] Severe sepsis is defined as sepsis that is complicated by end-organ dysfunction, as signaled by altered mental status, an episode of hypotension, elevated creatinine concentration, or evidence of disseminated intravascular coagulopathy.[8] The finding of elevated plasma levels of BNP or NT-pro BNP in sepsis over a decade ago has resulted in an ongoing search for a meaningful role of the hormone in clinical practice. BNP has been shown to be a useful cardiac biomarker for the identification of patients with suspected heart failure.[2] In the presence or absence of cardiac dysfunction, the concentrations of BNP increase in patients with severe sepsis or septic shock. In a recently published study, BNP was found to be significantly elevated in patients with septic shock in comparison with controls.[9‑12] There are not many studies from India. The present study was aimed to find out the relationship between elevated NT-pro BNP and mortality among patients who presented to ER with suspected sepsis. The secondary objective of the study was to find out correlation of NT-pro BNP with other laboratory and clinical parameters.

PATIENTS AND METHODS

All the patients who presented to the emergency department with suspected sepsis were included in the study after taking informed consent. Sepsis and septic shock were defined in accordance with the criteria of the consensus conference of the American College of Chest Physicians and Society of Critical Care Medicine.[7]

Blood sampling and determination of N-terminal prohormone of brain natriuretic peptide levels

All patients had blood samples taken for serum NT-pro BNP measurement within 6 h of admission. Serum NT-pro BNP was determined with a sandwich immunoassay on an Elecsys 2010 (Roche Diagnostics, Mannheim, Germany).

Ethics

Approval was obtained from our hospital’s Institutional Review Board.

Statistical analysis

Results are expressed as mean ± standard deviation (SD). The statistical analyses were done by SPSS version 17 (SPSS Statistics for Windows, SPSS Inc., Chicago). Comparison between the different groups studied was performed using analysis of variance, and the relations between the groups were determined using the post hoc correction for analysis of variance. Measurement of the mutual correspondence between two values was performed using the Spearman correlation coefficient. P <0.05 was considered statistically significant.

RESULTS

A total of 215 patients with sepsis were included in this study. The mean age of the cohort was 66.9 ± 12.72 years. There were 151 (69.3%) males and 63 (28.9%) females. The median NT-pro BNP was 2546 ng/ml (28–162150). Other laboratory parameters with mean and SD are shown in Table 1. In univariate analysis, [Table 2] NT-pro BNP, mechanical ventilation (MV), and DM were risk factors associated with mortality but in multivariate analysis [Table 3] showed significance only with MV and DM. In univariate analyses, NT-pro BNP, MV, blood culture positivity, chronic kidney disease-chronic liver disease (CKD-CLD), and diabetes mellitus were predictors of prolonged hospital stay, and it was same for multivariate analysis except for procalcitonin.

Table 1: Study population characteristics

| Characteristics | n (%)       | Mean±SD     |
|-----------------|-------------|-------------|
| Age (years)     | 215         | 66.9023±12.72442 |
| Mortality       | 19 (8.8)    | NA          |
| Duration of hospital stay | 215         | 13.4605±9.17723 |
| NT-pro BNP      | 215         | 7056.0657±16.12251608 |
| CRP (g/dl)      | 204         | 83.1555±79.01202 |
| Procalcitonin   | 131         | 20.9827±68.29153 |
| WBC count/ml³   | 212         | 12.8172±5.79570 |
| Platelet/ml³    | 212         | 486.8738±3970.75258 |
| Hb (gm/dl)      | 212         | 10.6381±1.97162 |
| Creatinine (mg/dL) | 208     | 3.5394±8.64248 |
| Urea            | 207         | 69.3271±50.98353 |
| Troponin I      | 185         | 17.8018±5.61299 |
| CKMB            | 164         | 22.6835±82.01054 |
| Serum bilirubin (mg/dL) | 192   | 1.2471±2.75848 |
| Need of MV      | 22 (10.2)   | NA          |

NT-pro BNP: N-terminal prohormone of brain natriuretic peptide, CRP: C-reactive protein, WBC: White blood cell, Hb: Hemoglobin, NA: Not applicable, MV: Mechanical ventilation, CKMB: Creatinine kinase-MB
Spearman’s correlation was done for checking the relation between BNP and other laboratory parameters. Values are shown in Table 4. The need of MV was the only clinical factor with a significant positive correlation associated with increased NT-pro BNP. There was no significant correlation between BNP and age, creatinine kinase-MB, urea, pyruvic transaminase, prothrombin time, blood culture, presence of DM, CLD, or CKD, and death.

**Table 2: Univariate analysis of risk factors and duration of hospital stay (t-test) and outcome**

| Risk factors          | Duration of hospital stay | Outcome |
|-----------------------|---------------------------|---------|
|                       | **χ²** | **P** | **OR** | **χ²** | **P** |
| Gender                | 64.5  | 0.38  | 0.19   | 0.907  |       |
| NT-pro BNP (>2546)    | 67.5  | <0.001| 0.343  | 4.23   | 0.040 |
| Blood culture         | 48.6  | 0.017 | 1.585  | 0.34   | 0.55  |
| Procalcitonin         | 1.329 | 0.48   | 0.489  |        |       |
| Mechanical ventilation| 53.5  | <0.001| 0.266  | 5.869  | 0.031 |
| Abnormal ECHO findings| 40.8  | 0.11  | 1.329  | 0.33   | 0.56  |
| DM                    | 58.0  | <0.001| 9.19   | 20.7   | <0.001|
| CLD/CKD               | 57.1  | <0.001| 0.93   | 0.01   | 0.38  |

**Table 3: Multivariate analysis for the variables for DHS and outcome**

| Risk factors          | Duration of hospital stay | Outcome |
|-----------------------|---------------------------|---------|
|                       | **χ²** | **P** | **OR** | **χ²** | **P** |
| NT-pro BNP            | <0.001|       | 0.343  | 4.23   | 0.031 |
| Blood culture         | 0.600 |       | 1.585  | NA     | NA    |
| Procalcitonin         | 0.129 | 0.251 | 1.829  | NA     | NA    |
| Mechanical ventilation| <0.001|       | 0.251  | 42.2   | 0.012 |
| DM                    | 0.025 |       | 8.19   | 20.7   | <0.001|
| CLD/CKD               | <0.001|       | 0.93   | NA     | NA    |

**Table 4: Correlation between brain natriuretic peptide levels and the studied parameters of all groups**

| Parameters          | Correlation coefficient | **P** |
|---------------------|-------------------------|-------|
| Age                 | −0.021                  | 0.765 |
| Duration of hospital stay | 0.043 | 0.534 |
| Trop I              | 0.340                   | <0.001|       |
| CKM                 | −0.181                  | 0.018 (NS) |
| Procalcitonin       | 0.108                   | 0.202 |
| Serum creatinine    | 0.240                   | <0.001(S) |
| Mechanical ventilation | 0.317 | <0.001(S) |
| ECHO                | 0.084                   | 0.222 |
| Blood culture       | −0.046                  | 0.560 |
| DM                  | −0.051                  | 0.458 |
| CLD/CKD             | 0.157                   | 0.005(S) |
| Outcome             | −0.140                  | 0.040 (NS) |
| CRP                 | 0.013                   | 0.786 |
| Albumin             | −0.002                  | 0.970 |
| LV systolic dysfunction | 0.049 | 0.384 |
| Blood culture       | 0.022                   | 0.731 |

**DISCUSSION**

BNP or NT-pro BNP levels may be a powerful predictor of mortality in patients with sepsis. This test appears to represent a rapid and relatively inexpensive method to enhance mortality prediction in sepsis and elevated natriuretic peptides are associated significantly with an increased risk of mortality. NT-pro BNP increase in patients with sepsis can be considerably high, even in the absence of cardiac pathology, but normal BNP levels can be used to rule out cardiac disorders. High plasma levels of BNP levels are associated with poor outcomes of sepsis. As well as, despite initial recovery from critical illness requiring intensive care unit (ICU) admission, many patients remain at risk of subsequent deterioration and death.

Our study was aimed at estimating the role of BNP as a marker of sepsis among adult patients admitted with sepsis and to identify the risk factors which are predictors of short-term mortality as well as duration of hospital stay. The mortality rate was found to be 8.8% in the present study. The present study showed a significant correlation between elevated BNP and sepsis-related mortality (P = 0.031). These data are in agreement with those of Baptista et al. There was a highly significant increase in BNP levels among the septic shock patients in comparison with severe sepsis patients and this was in agreement with Wang et al. The patient population varied across studies: three studies included patients with sepsis and nine studies included patients with severe sepsis or septic shock. These studies were carried out in various departments including the emergency department, medical ICU, surgical ICU, and general ICU.

Spearman’s correlation showed concordance between BNP levels and trop I and serum creatinine. However, there was no significant association between BNP levels and CK Mb, urea, albumin, procalcitonin, or CRP. These data are in agreement with those of Baptista et al. Diabetes mellitus, need of MV, NT-pro BNP (>2546), and chronic respiratory disorders were found to be associated with mortality, an observation similar to the Outcomerea study. Neither blood culture positivity nor elevated procalcitonin was found to be significantly related to mortality.

MV was required in 22 (10.2%) of the 215 patients treated for severe sepsis as most of the patients had respiratory failure. Out of 22 ventilated patients, five (22.72%) patients succumbed despite the interventions. The MV was associated with higher mortality as seen in study by Vincent et al. This observation was statistically significant implying that undergoing invasive MV could be a predictor of mortality in sepsis. On multivariate logistic regression analysis, invasive MV in patients with severe
sepsis was identified to be an independent predictor of mortality.

In this study, the mean platelet count, CRP, serum bilirubin, or urea were not identified as an independent predictor of mortality. This observation was in discordance with other studies. The reason may be lower mortality and low number of patients with severe sepsis in the present study. There was a significant difference in the mean values of serum creatinine among the survivors and nonsurvivors. This was in similar to a study by Oppert et al., who had found renal failure a significant independent risk factor for mortality in patients with sepsis and septic shock.[21]

The secondary outcome of the study was duration of hospital stay. Study showed that elevated NT-pro BNP, need of MV, comorbidities such as DM, CKD, or CLD had a significant correlation with increased duration of hospital stay. This finding was similar to other studies.[11-18]

**SUMMARY AND CONCLUSION**

There was a statistically significant correlation between NT-pro BNP levels and mortality. The other factors associated with increased mortality were diabetes mellitus and need of MV. In addition to the above factors, the presence of CKD and CLD was associated with increased duration of hospital stay. There was concordance between increased NT-pro BNP and elevated tropon I, serum creatinine, need of MV, and CKD.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8.
2. Goetze JP, Christoffersen C, Perko M, Arendrup M, Rehfeld JF, Kastrup J, et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 2003;17:1105-7.
3. Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: Molecular aspects. Eur J Heart Fail 2004;6:261-8.
4. Mauda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular enddiastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;35:825-32.
5. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.
6. Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirov R, Lenert L, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001;37:379-85.
7. Logeat D, Saudubray J, Beye P, Thabut G, Ennezat PV, Chavelas C, et al. Doppler echocardiography was more accurate than B-type natriuretic peptide assay for detecting CHF in acute dyspnea. Am Coll Cardiol 2002;40:1794-800.
8. Seymour CW, Liu VX, Iwashyna TJ, Brunckhorst FM, Rea TD, Scherag A, et al. Assessment of clinical criteria for sepsis: For the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016;315:762-74.
9. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003;31:1250-6.
10. Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001;39:571-88.
11. Clerico A. Pathophysiological and clinical relevance of circulating levels of cardiac natriuretic hormones: Are they merely markers of cardiac disease? Clin Chem Lab Med 2002;40:752-60.
12. Charpentier J, Luyt CE, Fulla Y, Vinsonneau C, Cariou A, Grabar S, et al. Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 2004;32:660-5.
13. Wang F, Wu Y, Tang L, Zhu W, Chen F, Xu T, et al. Brain natriuretic peptide for prediction of mortality in patients with sepsis: A systematic review and meta-analysis. Crit Care 2012;16:R74.
14. Maeder M, Ammann P, Kiowski W, Rickli H. B-type natriuretic peptide in patients with sepsis and preserved left ventricular ejection fraction. Eur J Heart Fail 2005;7:1164-7.
15. Kandil E, Burack J, Sawas A, Bibawy H, Schwartzman A, Zenilman ME, et al. B-type natriuretic peptide: A biomarker for the diagnosis and risk stratification of patients with septic shock. Arch Surg 2008;143:242-6.
16. Metnitz PG, Fieux F, Jordan B, Lang T, Moreno R, Le Gall JR. Critically ill patients readmitted to intensive care units – Lessons to learn? Intensive Care Med 2003;29:241-8.
17. Baptista R, Jorge E, Sousa E, Pimentel J. B-type natriuretic peptide predicts long-term prognosis in a cohort of critically ill patients. Heart Int 2011;6:e18.
18. Pernman SM, Chang AM, Hollander JE, Gaisieski DF, Trzeciak S, Birkhahn R, et al. Relationship between B-type natriuretic peptide and adverse outcome in patients with clinical evidence of sepsis presenting to the emergency department. Acad Emerg Med 2011;18:219-22.
19. Schellenberger U, O’Rea J, Guzzetta A, Jue RA, Trzeciak S, Protter AA, Porrill NS. The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch Biochem Biophys 2006;451:160-6.
20. Vincent JL, Jones G, David S, Cadwell KK. Frequency and mortality of septic shock in Europe and North America: A systematic review and meta-analysis. Crit Care 2012;16:R74.
21. Oppert M, Engel C, Brunckhorst FM, Bogatsch H, Reinhart K, Frei U, et al. Competence Network Sepsis (Sepnet). Acute renal failure in patients with severe sepsis and septic shock—a significant independent risk factor for mortality: results from the German Prevalence Study. Nephrol Dial Transplant 2008;23:904-9. doi: 10.1093/ndt/gfm610. Epub 2007 Dec 7. PMID: 18065435.